# Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate

> **NCT00483327** · PHASE2 · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 31 (actual)

## Conditions studied

- Atypical Endometrial Hyperplasia
- Endometrial Carcinoma

## Interventions

- **DRUG:** Megestrol Acetate

## Key facts

- **NCT ID:** NCT00483327
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2018-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00483327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00483327, "Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00483327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*